On August 28, Insmed rose 5.87% in pre-market trading, trading at $120.9/share, with Turnover of $604.5.

On the news front, Japan's Ministry of Health, Labour and Welfare officially approved Insmed's core drug Brinsupri for treating non-cystic fibrosis bronchiectasis in patients aged 12 and older. The approval was based on a phase 3 study demonstrating the drug reduced lung-related flare-ups, delayed time to first flare-up compared with placebo, helped preserve lung function, and was generally well tolerated.

With this approval, Brinsupri is now commercially available in the US, Europe, and Japan, completing its global commercialization across three major markets. The company's Q2 earnings report showed Brinsupri global revenue reached $309 million, exceeding market expectations, and management raised full-year Brinsupri revenue guidance to $1.25 billion to $1.4 billion. RBC Capital Markets maintains an outperform rating with a $195 target price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)